Promoted Content
Promoted Content

Find Novel Neurology Drugs in Preclinical Development in CANADA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyltryptamine

            Therapeutic Area: Neurology Product Name: AP-188

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Algernon Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 19, 2021

            Details:

            Algernon Pharmaceuticals has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (“N,N-Dimethyltryptamine or DMT”), to Canadian-based Dalton Pharma Services.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Revive Therapeutics

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition February 17, 2021

            Details:

            All intellectual and work property derived from pre-clinical research activities from the National Health Research Institutes (“NHRI”) in traumatic brain injury and stroke, as it relates to psilocybin with the aim to obtain FDA Orphan Drug Designation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): N,N-Dimethyltryptamine

            Therapeutic Area: Neurology Product Name: AP-188

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 01, 2021

            Details:

            Algernon has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Progranulin,Alpha-602

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2020

            Details:

            Alpha Cognition has been granted 2 EU patents relating to the use of progranulin to treat neurodegenerative diseases. Progranulin, alpha-602, is a protein, capable of protecting stressed neurons.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabis derivatives

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2020

            Details:

            Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions.